| 10.38 Delayed Data As of Feb 21 |  +0.23 / +2.27%Today’s Change | 3.75 Today|||52-Week Range 16.86 | +82.43% Year-to-Date |
| 4 Reasons Why Marijuana Stocks & ETFs Could Be on a High in 2019 Feb 15 / Zacks.com - Paid Partner Content | Why Marijuana ETFs are on a High in 2019 Feb 14 / Zacks.com - Paid Partner Content |
| Previous close | 10.15 |
| Today’s open | 10.27 |
| Day’s range | 10.20 - 10.53 |
| Volume | 7,401,154 |
| Average volume (3 months) | 7,329,261 |
| Market cap | $2.4B |
| Earnings growth (last year) | +342.55% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +87.91% |
| P/E ratio | 39.2 |
| Price/Sales | 50.76 |
| Price/Book | 2.24 |
| Today’s change | Today’s % change | |
|---|---|---|
| USNAUSANA Health Science... | +3.92 | +3.94% |
| ARGXargenx SE | -3.13 | -2.50% |
| CRONCronos Group Inc | +0.24 | +1.08% |
| LJPCLa Jolla Pharmaceuti... | +0.09 | +1.54% |
| Next reporting date | -- |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $27.8M |
| Annual profit (last year) | $22.1M |
| Net profit margin | 79.77% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chief Executive Officer & Director Victor Neufeld |
President Jakob Ripshtein |
Corporate headquarters Leamington, Ontario |
